| Safety and efficacy of weekly nab(R)-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. | |
| | |
MedLine Citation:
|
PMID: 23123509 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BackgroundThis analysis evaluates safety and efficacy in elderly (≥70 years old) versus younger patients enrolled in a phase III advanced non-small-cell lung cancer (NSCLC) trial.Patients and MethodsUntreated stage IIIB/IV patients with PS 0/1 were randomly assigned (1:1) to carboplatin AUC6, day 1 every 3 weeks, and either nab-paclitaxel (Abraxane) 100 mg/m(2) weekly (nab-P/C) or solvent-based paclitaxel (Taxol) 200 mg/m(2) day 1 every 3 weeks (sb-P/C). The primary end-point was overall response rate (ORR).ResultsFifteen percent of 1052 enrolled patients were elderly: nab-P/C, n = 74; sb-P/C, n = 82. In both age cohorts, the ORR was higher with nab-P/C versus sb-P/C (age ≥70: 34% versus 24%, P = 0.196; age <70: 32% versus 25%, P = 0.013). In elderly patients, progression-free survival (PFS) trended in favor of nab-P/C (median 8.0 versus 6.8 months, hazard ratio (HR) 0.687, P = 0.134), and overall survival (OS) was significantly improved (median 19.9 versus 10.4 months, HR 0.583, P = 0.009). In younger patients, PFS (median 6.0 versus 5.8 months, HR 0.903, P = 0.256) and OS (median 11.4 versus 11.3 months, HR 0.999, P = 0.988) were similar in both arms. Adverse events were similar in both age groups, with less neutropenia (P = 0.015), neuropathy (P = 0.001), and arthralgia (P = 0.029), and increased anemia (P = 0.007) with nab-P/C versus sb-P/C.ConclusionsIn elderly NSCLC patients, nab-P/C as first-line therapy was well tolerated and improved the ORR and PFS, with substantially longer OS versus sb-PC. |
| | |
Authors:
|
M A Socinski; C J Langer; I Okamoto; J K Hon; V Hirsh; S R Dakhil; R D Page; J Orsini; H Zhang; M F Renschler |
Related Documents
:
|
2244019 - The importance of vocal cord mobility in t2 laryngeal cancer. 11954939 - T2 laryngeal carcinoma with impaired mobility: subtypes with therapeutic implications. 23154549 - Can determination of circulating endothelial cells and serum caspase-cleaved ck18 predi... 23144319 - Prognostic implications of genetic variants in advanced non-small cell lung cancer: a g... 3230999 - Comparison of local tumor recurrence following excision with the co2 laser, nd:yag lase... 23327989 - Acute cerebrovascular accident after cisplatin treatment in a patient taking letrozole. 22560549 - Fractionated stereotactic radiotherapy of vestibular schwannomas accelerates hearing loss. 1071939 - Severe arterial hypertension (grade iii and iv). 18381939 - Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-2 |
Journal Detail:
|
Title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Volume: - ISSN: 1569-8041 ISO Abbreviation: Ann. Oncol. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-5 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007735 Medline TA: Ann Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
University of Pittsburgh Medical Center, Division of Hematology/Oncology, Pittsburgh. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in p...
Next Document: Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiativ...